BD² awards $6.1 million for bipolar disorder evaluation, treatment hub
The Feinstein Institutes for Medical Research in Manhasset, New York, has announced a $6.1 million grant from BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder to serve as a hub for six bipolar disorder evaluation and treatment sites across the United States.
The Clinical Coordinating Center, housed at Zucker Hillside Hospital in Glen Oaks, New York—part of the Northwell Health hospital system—will collaborate with sites that include Mass General Brigham’s McLean Hospital, the University of California Los Angeles, Johns Hopkins University, the Mayo Clinic, the University of Michigan, and UTHealth Houston. Each site will evaluate patients and collectively offer treatment and clinical trial options using cutting-edge biotechnology, big data analytics, and a combined data ecosystem to address bipolar disorder with a focus on innovation and equity.
The center is led by Feinstein Institute of Behavioral Science co-director Anil K. Malhotra and Patricia Marcy, executive director of Vanguard Research Group, a Northwell Health joint venture that conducts clinical trials and related research.
“Although bipolar disorder impacts millions of Americans every year, it is under-researched,” said Feinstein Institutes president Kevin J. Tracey. “With this significant support and Dr. Malhotra’s leadership, we’ll produce knowledge about bipolar disorder that will benefit those living with it.”
(Photo credit: Getty Images/People Images)
Related content
